$SMMT · Summit Therapeutics Inc.
Summit Therapeutics filed an 8-K reporting Q3 2026 results and a special-meeting vote. Net loss was $208.4M for the quarter ($0.26/share) versus $231.8M a year earlier, with R&D expense of $169.1M. Stockholders approved Amendment No. 3 doubling authorized common shares from 1 billion to 2 billion. The company closed Q3 with $629.8M in cash and investments and received $2.0B from AstraZeneca post-quarter.
- Q3 net loss narrowed to $208.4M from $231.8M a year earlier.
- R&D expense rose to $169.1M in Q3 from $131.1M a year earlier.
- Authorized common shares doubled to 2 billion via Amendment No. 3.
- Cash and investments totaled $629.8M at September 30, 2026.
- AstraZeneca's $2B strategic equity investment closed after quarter-end.
Extended-hours last trade $16.12, down 0.31% vs regular close and 0.37% vs price-at-filing, a muted reaction to the loss and share-authorization increase.
A $2B strategic investment and a near-term FDA decision collide with a doubling of authorized shares and a $208M quarterly loss.
The $2B AstraZeneca investment and expanding clinical collaborations underscore large-pharma validation of ivonescimab across multiple solid-tumor indications.
The FDA has stated a statistically significant OS benefit is necessary for HARMONi approval, but the OS primary endpoint showed only a positive trend without statistical significance. The share-authorization doubling signals potential future dilution.